FDAnews Drug Daily Bulletin
Pharmaceuticals / Regulatory Affairs

Pennsylvania Supreme Court Grants Appeal that Could Impact Pending Risperdal Cases

July 17, 2018

The Pennsylvania Supreme Court has agreed to hear an appeal on the statute of limitations associated with two lawsuits filed against the manufacturers of antipsychotic drug Risperdal (risperidone).

A short document issued by the court on July 5 announced that two Risperdal cases against Johnson & Johnson and Janssen would be heard. The issues at hand are the relevant statute of limitations and at what time the plaintiffs should have been aware of Risperdal’s risks.

The ruling could have an impact on thousands of Risperdal cases currently pending in Pennsylvania.

View today's stories